SELLAS Life Sciences Group Earnings Call Transcripts
Fiscal Year 2026
-
The meeting saw strong shareholder support for all proposals, including director elections, auditor ratification, and an expanded equity plan. Financial performance was robust, with significant growth in market cap and cash reserves, while late-stage clinical programs advanced toward key data milestones.
-
GPS is nearing pivotal phase III data in AML, with delayed event accrual suggesting longer survival and strong prior efficacy. SLS009 shows high response rates in venetoclax-resistant AML, with top-line phase II data expected by year-end.
-
Late-stage oncology company advancing GPS (phase III, AML maintenance) and SLS-009 (phase II, frontline AML), both showing strong efficacy and safety signals. Key data readouts for both assets are expected by year-end, supported by a robust $110M cash position.
-
The company is advancing two late-stage oncology assets, GPS and SLS009, both targeting AML with promising survival and response data. Imminent catalysts include phase III REGAL trial results for GPS and phase II data for SLS009, supported by strong biomarker strategies and financial resources.
Fiscal Year 2025
-
Late-stage programs GPS and SLS009 show strong clinical promise in AML, with GPS nearing pivotal REGAL trial results and SLS009 advancing to frontline studies. Financial position is robust, supporting key milestones and commercialization planning, with regulatory designations and FDA engagement accelerating development.
Fiscal Year 2024
-
The phase III REGAL study for GPS in AML has reached its interim analysis trigger, with the IDMC set to review efficacy, futility, and safety in January. Outcomes may include trial continuation, modification, or early stopping for efficacy or futility.